ClearNote Health Initiates Landmark Clinical Study to Improve Pancreatic Cancer Detection

Strategic Insights -

ClearNote Health has announced the initiation of a major clinical study to enhance early detection for pancreatic cancer, a disease responsible for over 455,000 deaths worldwide each year. The Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study, sponsored by University Hospital Southampton NHS Foundation Trust, aims to identify early pancreatic cancer signals in individuals with recently diagnosed type 2 diabetes. This population is up to eight times more likely to develop pancreatic cancer compared to the general public.

Key Takeaways:

  • The SAFE-D study will enroll up to 15,000 patients with newly diagnosed type 2 diabetes and will be the largest study of its kind to date.
  • Patients with newly diagnosed type 2 diabetes are at a significantly higher risk of developing pancreatic cancer, with up to an eight-fold increase in risk compared to the general population.
  • The Avantect Pancreatic Cancer Test, developed by ClearNote Health, uses a blood-based approach to detect pancreatic cancer by analyzing epigenomic biomarkers and genomic data.
  • The test has the potential to identify pancreatic cancer at its earliest and most treatable stages, with the goal of improving patient outcomes and saving lives.
  • The study is led by Zaed Hamady, consultant pancreatic cancer surgeon at University Hospital Southampton, and will be conducted by researchers at the Southampton Clinical Trials Unit (CTU) based at the University of Southampton.
  • The study's community-focused approach aims to make early cancer detection research more inclusive and equitable, with the goal of increasing access to healthcare and clinical trials for underserved populations.

Statistics:

  • Pancreatic cancer is responsible for over 455,000 deaths worldwide each year (Source: World Health Organization).
  • Patients with newly diagnosed type 2 diabetes are up to eight times more likely to develop pancreatic cancer compared to the general public (Source: ClearNote Health).
  • The SAFE-D study aims to enroll up to 15,000 patients with newly diagnosed type 2 diabetes (Source: University Hospital Southampton NHS Foundation Trust).
  • The Avantect Pancreatic Cancer Test has the potential to benefit thousands of people in the UK by identifying pancreatic cancer at its earliest and most treatable stages (Source: ClearNote Health).

Sources:

  • ClearNote Health. (2023). ClearNote Health Initiates Landmark Clinical Study to Improve Pancreatic Cancer Detection.
  • World Health Organization. (2022). GLOBOCAN 2022.
  • University Hospital Southampton NHS Foundation Trust. (2023). University Hospital Southampton NHS Foundation Trust and ClearNote Health Collaborate on Landmark Clinical Study to Improve Early Detection of Pancreatic Cancer.